Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM) Who Are Eligible for Autologous Stem Cell Transplantation: Multicenter Phase 2 Study
This study aims to assess the efficacy and toxicities of CTD and Vel-CD induction followed
by high-dose therapy with autologous stem cell transplantation as a first line treatment for
the patients with multiple myeloma.The investigators already investigated the
thalidomide-based chemotherapy in patients with newly diagnosed MM. The combined regimen
consisted of cyclophosphamide, thalidomide and dexamethasone (CTD) for induction treatment.
CTD chemotherapy resulted in a favorable response with 79.4% overall response rate including
42.6% complete response (CR) or very good partial complete response (VGPR), and tolerable
toxicity in MM patients. Moreover, CTD chemotherapy did not affect the yield of the stem
cell collection.The investigators also published that the clinical efficacy and safety of a
four-drug combination of bortezomib, cyclophosphamide, thalidomide, and dexamethasone was
assessed for patients with relapsed or refractory multiple myeloma Vel-CTD chemotherapy.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
response rate for induction chemotherapy
Korea: Institutional Review Board